Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo.

[1]  M. Hori,et al.  Electroporation-mediated gene transfer that targets glomeruli. , 2001, Journal of the American Society of Nephrology : JASN.

[2]  J. Murphy-Ullrich,et al.  Activation of latent TGF-β by thrombospondin-1: mechanisms and physiology , 2000 .

[3]  S. Schultz-Cherry,et al.  The Activation Sequence of Thrombospondin-1 Interacts with the Latency-associated Peptide to Regulate Activation of Latent Transforming Growth Factor-β* , 1999, The Journal of Biological Chemistry.

[4]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[5]  Rainer M. Bohle,et al.  Real-time quantitative RT–PCR after laser-assisted cell picking , 1998, Nature Medicine.

[6]  L. Wakefield,et al.  Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency , 1998, Nature Medicine.

[7]  R. Hynes,et al.  Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo , 1998, Cell.

[8]  H. Tada,et al.  The Fibronectin Production Is Increased by Thrombospondin via Activation of TGF-β in Cultured Human Mesangial Cells , 1998, Nephron.

[9]  R. Hynes,et al.  Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.

[10]  W. Couser,et al.  Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. , 1998, Kidney international.

[11]  M. Barcellos-Hoff,et al.  Latent transforming growth factor β1 activation in situ: quantitative and functional evidence after low‐dose γ‐irradiation 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  K. Csaky,et al.  Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. , 1997, The Journal of clinical investigation.

[13]  G. Boivin,et al.  TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. , 1997, Development.

[14]  H. Rupprecht,et al.  TGF-beta1-induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-cdk 2 activation and retinoblastoma protein phosphorylation. , 1997, Kidney international.

[15]  M. Kitamura,et al.  Mesangial cell-derived transforming growth factor-beta 1 reduces macrophage adhesiveness with consequent deactivation. , 1996, Kidney international.

[16]  S. Thorgeirsson,et al.  Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[17]  Y. Kaneda,et al.  Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. , 1996, Kidney international.

[18]  Y. Kaneda,et al.  Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney , 1996, Nature Medicine.

[19]  V. Kaartinen,et al.  Abnormal lung development and cleft palate in mice lacking TGF–β3 indicates defects of epithelial–mesenchymal interaction , 1995, Nature Genetics.

[20]  H. Kawachi,et al.  Transfer of a mutated gene encoding active transforming growth factor-beta 1 suppresses mitogenesis and IL-1 response in the glomerulus. , 1995, Kidney international.

[21]  W. Couser,et al.  Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. , 1995, Kidney international.

[22]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[23]  J. Galla.  IgA nephropathy. , 1995, Kidney international.

[24]  W. Border,et al.  Transforming Growth Factor β in Tissue Fibrosis , 1994 .

[25]  S. Schultz-Cherry,et al.  Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. , 1994, The Journal of biological chemistry.

[26]  R. Johnson,et al.  The glomerular response to injury: progression or resolution? , 1994, Kidney international.

[27]  K. Sharma,et al.  The emerging role of transforming growth factor-beta in kidney diseases. , 1994, The American journal of physiology.

[28]  P. Zech,et al.  Thrombospondin in human glomerulopathies. A marker of inflammation and early fibrosis. , 1994, The American journal of pathology.

[29]  D. Rifkin,et al.  An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. , 1994, Analytical biochemistry.

[30]  S. Schultz-Cherry,et al.  Thrombospondin causes activation of latent transforming growth factor- beta secreted by endothelial cells by a novel mechanism [published erratum appears in J Cell Biol 1993 Sep;122(5):following 1143] , 1993, Journal of Cell Biology.

[31]  E. Ruoslahti,et al.  Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease , 1992, Nature.

[32]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[33]  W. McGinnis,et al.  Antp‐type homeodomains have distinct DNA binding specificities that correlate with their different regulatory functions in embryos. , 1992, The EMBO journal.

[34]  E. Ruoslahti,et al.  Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.

[35]  M. Sporn,et al.  Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 , 1990, Nature.

[36]  G. D'Amico,et al.  The commonest glomerulonephritis in the world: IgA nephropathy. , 1987, The Quarterly journal of medicine.

[37]  M. Barcellos-Hoff.  Latency and activation in the control of TGF-β , 2005, Journal of Mammary Gland Biology and Neoplasia.

[38]  J. Munger.  The integrin αvβ6 binds and activates latent TGFβ1 : A mechanism for regulating pulmonary inflammation and fibrosis , 1999 .

[39]  G. Boivin,et al.  TGF β 2 knockout mice have multiple developmental defects that are non-overlapping with other TGF β knockout phenotypes , 1997 .

[40]  Stacey Schul tz-Cherry.  Thrombospondin Causes Activation of Latent Transforming Growth Factor-Secreted by Endothelial Cells by a Novel Mechanism , 2002 .

[41]  D. Rifkin,et al.  Control of transforming growth factor-β activity: Latency vs. activation , 1992 .